Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn's Disease Treated Until 33 Weeks of Gestation. (16th October 2017)

• Record Type: Journal Article
• Authors: Rowan, Catherine R; Cullen, Garret; Mulcahy, Hugh E; Keegan, Denise; Byrne, Kathryn; Murphy, Deirdre J; Sheridan, Juliette; Doherty, Glen A
• Is Part Of: Journal of Crohn's and colitis. Volume 12:Number 3(2018:Mar.)
• Page Start: 376
• Page End: 378
• Publication Date: 2017-10-16
• Subjects: Ustekinumab -- pregnancy -- trough concentrations; Inflammatory bowel diseases -- Periodicals; 616.344005
• DOI: 10.1093/ecco-jcc/jjx141
• Languages: English
• ISSNs: 1873-9946

Abstract

Abstract: A 35-year old woman with ileocolonic, perianal, and vulval Crohn's disease was treated with subcutaneous ustekinuamb [USK] throughout pregnancy. Dose intervals were shortened from 6-weekly to 4-weekly to maintain clinical remission. The last dose of USK was administered at 33 weeks of gestation, and a healthy baby boy was delivered by caesarean section at 37 weeks. Maternal trough USK levels remained stable during pregnancy. Cord blood USK levels were nearly 2-fold higher than contemporaneous maternal serum levels. To our knowledge, this is the first report of maternal and cord USK levels in a patient with Crohn's disease.